This means that young females with both abnormally low and abnormally high prolactin production may be more prone to cardiovascular and metabolic complications later in life and overtreatment of hyperprolactinemia does not seem to reduce the risk of cardiometabolic complications associated with prolactin excess. This evidence concerns the gene PRL and Increased circulating prolactin concentration.